ProfileGDS5678 / 1434304_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 86% 84% 85% 86% 81% 80% 80% 78% 88% 90% 88% 89% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2491285
GSM967853U87-EV human glioblastoma xenograft - Control 26.5836886
GSM967854U87-EV human glioblastoma xenograft - Control 36.284484
GSM967855U87-EV human glioblastoma xenograft - Control 46.5425585
GSM967856U87-EV human glioblastoma xenograft - Control 56.6007186
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6076981
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.516980
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6994280
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4066178
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.9680688
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.2219190
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8736388
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.9925489
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.9570289